miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC

Radiotherapy (RT) plus the anti‐EGFR monoclonal antibody Cetuximab (CTX) is an effective combination therapy for a subset of head and neck squamous cell carcinoma (HNSCC) patients. However, predictive markers of efficacy are missing, resulting in many patients treated with disappointing results and...

Descripción completa

Detalles Bibliográficos
Autores principales: Citron, Francesca, Segatto, Ilenia, Musco, Lorena, Pellarin, Ilenia, Rampioni Vinciguerra, Gian Luca, Franchin, Giovanni, Fanetti, Giuseppe, Miccichè, Francesco, Giacomarra, Vittorio, Lupato, Valentina, Favero, Andrea, Concina, Isabella, Srinivasan, Sanjana, Avanzo, Michele, Castiglioni, Isabella, Barzan, Luigi, Sulfaro, Sandro, Petrone, Gianluigi, Viale, Andrea, Draetta, Giulio F, Vecchione, Andrea, Belletti, Barbara, Baldassarre, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261495/
https://www.ncbi.nlm.nih.gov/pubmed/34062049
http://dx.doi.org/10.15252/emmm.202012872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261495/
https://www.ncbi.nlm.nih.gov/pubmed/34062049
http://dx.doi.org/10.15252/emmm.202012872

Ejemplares similares